Top
Summary
All studies
Mortality
Hospitalization
Serious outcomes
Cases
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
All adintrevimab studies
 
Feedback
Home
c19early.org COVID-19 treatment researchAdintrevimabAdintrevimab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Outcomes in COVID-19 adintrevimab studies

Outcomes in adintrevimab studies. mAb use may create new variants that spread globally Focosi, Leducq, and may be associated with prolonged viral loads, clinical deterioration, and immune escape Casadevall, Choudhary, Günther, Leducq.
0 0.5 1 1.5+ All studies 43% 2 2,483 Improvement, Studies, Patients Relative Risk Mortality 43% 2 2,483 Hospitalization 83% 2 1,831 Cases 71% 2 1,831 RCTs 43% 2 2,483 RCT mortality 43% 2 2,483 Prophylaxis 43% 2 2,483 Adintrevimab for COVID-19 c19early.org October 2024 Favorsadintrevimab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] death 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] death 0/240 1/241 Tau​2 = 0.00, I​2 = 0.0%, p = 0.48 Prophylaxis 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk All studies 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk 2 adintrevimab COVID-19 studies c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.48 Effect extraction pre-specified(most serious outcome) Favors adintrevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] 0/240 1/241 Tau​2 = 0.00, I​2 = 0.0%, p = 0.48 Prophylaxis 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk All studies 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk 2 adintrevimab COVID-19 mortality results c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.48 Favors adintrevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EVADE PrEP Ison (DB RCT) 84% 0.16 [0.02-1.34] hosp. 1/752 6/728 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 80% 0.20 [0.01-4.15] hosp. 0/175 2/176 Tau​2 = 0.00, I​2 = 0.0%, p = 0.047 Prophylaxis 83% 0.17 [0.03-0.98] 1/927 8/904 83% lower risk All studies 83% 0.17 [0.03-0.98] 1/927 8/904 83% lower risk 2 adintrevimab COVID-19 hospitalization results c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.047 Favors adintrevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] death 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] death 0/240 1/241 Tau​2 = 0.00, I​2 = 0.0%, p = 0.48 Prophylaxis 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk All studies 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk 2 adintrevimab COVID-19 serious outcomes c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.48 Effect extraction pre-specified(most serious outcome) Favors adintrevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EVADE PrEP Ison (DB RCT) 70% 0.30 [0.16-0.56] symp. case 12/752 39/728 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 75% 0.25 [0.07-0.88] symp. case 3/175 12/176 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Prophylaxis 71% 0.29 [0.16-0.51] 15/927 51/904 71% lower risk All studies 71% 0.29 [0.16-0.51] 15/927 51/904 71% lower risk 2 adintrevimab COVID-19 case results c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Favors adintrevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] death 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] death 0/240 1/241 Tau​2 = 0.00, I​2 = 0.0%, p = 0.48 Prophylaxis 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk All studies 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk 2 adintrevimab COVID-19 Randomized Controlled Trials c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.48 Effect extraction pre-specified(most serious outcome) Favors adintrevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] 0/240 1/241 Tau​2 = 0.00, I​2 = 0.0%, p = 0.48 Prophylaxis 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk All studies 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk 2 adintrevimab COVID-19 RCT mortality results c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.48 Favors adintrevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] death 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] death 0/240 1/241 Tau​2 = 0.00, I​2 = 0.0%, p = 0.48 Prophylaxis 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk All studies 43% 0.57 [0.12-2.69] 2/1,241 4/1,242 43% lower risk 2 adintrevimab COVID-19 peer reviewed studies c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.48 Effect extraction pre-specified(most serious outcome) Favors adintrevimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ EVADE PrEP Ison (DB RCT) 33% 0.67 [0.11-3.98] death 2/1,001 3/1,001 Improvement, RR [CI] Treatment Control EVADE PrEP Ison (DB RCT) 50% 0.50 [0.13-1.99] death 3/1,001 6/1,001 EVADE PrEP Ison (DB RCT) 84% 0.16 [0.02-1.34] death 1/752 6/728 EVADE PrEP Ison (DB RCT) 84% 0.16 [0.02-1.34] hosp. 1/752 6/728 EVADE PrEP Ison (DB RCT) 70% 0.30 [0.16-0.56] symp. case 12/752 39/728 EVADE PEP Ison (DB RCT) 67% 0.33 [0.01-8.15] death 0/240 1/241 EVADE PEP Ison (DB RCT) 80% 0.20 [0.01-4.15] death 0/240 2/241 EVADE PEP Ison (DB RCT) 80% 0.20 [0.01-4.15] hosp. 0/175 2/176 EVADE PEP Ison (DB RCT) 75% 0.25 [0.07-0.88] symp. case 3/175 12/176 Adintrevimab COVID-19 outcomes c19early.org October 2024 Favors adintrevimab Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit